Skip to main content

Table 2 Cohort 2: University of Arizona and Arizona Donor Network: COPD patients and controls

From: Paradoxical effects of cigarette smoke and COPD on SARS-CoV-2 infection and disease

 

N

NS

Smokers

COPD

P

Total participants (N)

47

10

16

21

 

Age

47

56 ± 18*a

67 ± 6

66 ± 9

P < 0.01a

Gender (M/F)

47

7/3

7/9

12/9

NS

Smoking history (pack years)

47

0

33 ± 15***

38 ± 21***

P < 0.001

Smoking habit (current/former smoker)

47

0

6/10

5/16

NS

Spirometry

43

7

16

20

 

FEV1 (% predicted)

43

77 ± 16

88 ± 21

40 ± 24***^

P < 0.001

FEV1/FVC

43

82 ± 7

80 ± 9

41 ± 18***^

P < 0.001

Comorbidities

47

10

16

21

 

Hypertension N (%)

47

5 (50%)

9 (56%)

11 (52%)

NS

Other cardiovascluar diseases N (%)

47

1 (10%)

5 (31%)

5 (24%)

NS

Diabetes mellitus N (%)

47

2 (20%)

2 (13%)

4 (19%)

NS

Medications

45

8

16

21

 

Inhaled corticosteroids N (%)

45

0

4 (25%)

10 (48%)§

P < 0.05

LABA/SABA/LAMA N (%)

45

0

6 (38%) §

17 (81%)***#

P < 0.01

Oral corticosteroids N (%)

45

1 (13%)

0

3 (14%)

NS

ACEi/ARB N (%)

45

3 (38%)

4 (44%)

9 (43%)

NS

Ca Antagonists/B-blockers N (%)

45

2 (25%)

6 (38%)

6 (29%)

NS

Diuretics N (%)

45

2 (25%)

5 (31%)

2 (10%)

NS

  1. Data are mean ± SD, unless specified
  2. NS never-smokers
  3. *P < 0.01 versus Smokers and COPD patients; §P < 0.05 compared to NS; °P < 0.001 compared to smokers and NS; ***P < 0.001 compared to NS; #P < 0.01 compared to NS. ^P < 0.001 compared to smokers
  4. aDue to the significant difference in age between NS versus COPD and Smokers, ACE2 levels were corrected for age using linear regression models